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anolazine and Its
nti-Ischemic Effects
evisiting an Old
echanistic Paradigm Anew?*
illiam E. Boden, MD
uffalo, New York
eventy-five years ago, Tennant and Wiggers (1) first
escribed the pathophysiologic effects of coronary occlusion
n myocardial contraction and were the first to document
he sequence of ischemia-mediated perturbations of both
egional and global systolic and diastolic function during
cute myocardial ischemia. In these seminal observations,
he authors were the first to describe segmental diastolic
ysfunction followed closely by systolic aneurysmal bulging
s the earliest manifestations of acute myocardial ischemia.
See page 934
ince that time, our scientific understanding of the conse-
uences of myocardial ischemia has been viewed through
he pathophysiologic lens of supply versus demand and how
he sequence of changes induced by coronary occlusion (or
ncreasing stenosis) might lead to objective findings of
schemia, hemodynamic and electrocardiographic abnor-
alities, and symptoms of angina. This sequence has often
een referred to as the “ischemia cascade” (2,3), wherein the
ery first abnormalities that occur are acute alterations in
egional lusitropic properties, followed by segmental systolic
ysfunction and acute alterations in left ventricular (LV)
echanical performance, after which electrocardiographic
epolarization changes are noted to occur (often 20 to 30 s
fter coronary occlusion). Clinically, anginal symptoms are
he last to occur in this temporal cascade.
As a result, the mechanistic principle that ischemia and
ngina are a fundamental consequence of a myocardial
xygen supply-demand imbalance is a remarkably simple
onstruct to understand and has provided the pathophysio-
ogic basis of our scientific understanding as to why phar-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, Division of Cardiovascular Medicine, State
niversity of New York at Buffalo Schools of Medicine and Public Health, Buffalo1
eneral Hospital, Buffalo, New York. Dr. Boden has given lectures for Gilead in
008 and 2009 for approximately $10,000 annually.acologic therapies that ameliorate the supply-demand
ismatch improve both angina and ischemia (4,5). Con-
entional anti-anginal therapies, including beta-blockers,
alcium-channel blockers (CCBs), and nitrates reduce myo-
ardial oxygen demand by reducing the hemodynamic
eterminants of heart rate (HR), systolic blood pressure
SBP), myocardial contractility, and wall tension (6–16). As
uch, these pharmacologic interventions exert their thera-
eutic benefits systemically by reducing the rate-pressure
roduct (RPP) both at rest and during exercise, as compared
ith placebo, which results in an attenuation of ischemia
hroughout the entire duration of exercise (from submaxi-
al to maximal). In essence, drugs like the beta-blockers
6–11) and CCBs (especially HR-lowering agents like
erapamil and diltiazem) (13–16) favorably alter hemody-
amic parameters and permit patients with ischemic heart
isease to exercise longer (and to a higher external work-
oad), even though the peak RPP reductions achieved with
ctive therapy might be the same as that achieved with
lacebo. Thus, a fundamental premise of such therapies that
educe global myocardial oxygen demand is that patients
emain below the physiologic or hemodynamic threshold at
hich ischemia and angina develop (4,5).
In this issue of the Journal, Stone et al. (17) marshal
ritically new scientific information that provides important
nsight into the mechanism of action of ranolazine in
atients with chronic angina and stable ischemic heart
isease. In their exceedingly detailed and comprehensive
ssessment of the effects of graded exercise on HR, SBP,
PP, and ischemic ST-segment depression (during sub-
aximal and maximal exercise) among 175 patients from
he MARISA (Monotherapy Assessment of Ranolazine In
table Angina) trial who were randomized to ranolazine
500, 1,000, or 1,500 mg twice daily) versus placebo, the
uthors used a novel statistical approach (a mixed model
epeated measures analysis of variance) where the changes in
PP and ST-segment depression could be compared within
ach of the respective exercise stages, taking into account
he treatment received (ranolazine vs. placebo), treatment
equence (differential ranolazine dosing), cross-over period,
he exercise stage, and the interaction of treatment with
xercise stage. Consequently, this careful explanatory anal-
sis provided the authors an opportunity to accurately assess
he dose-dependent effects of ranolazine on the change in
T-segment depression from pre-exercise (summed over 11
lectrocardiographic leads) through each stage of submaxi-
al to maximal exercise and controlled for RPP across the
xercise duration spectrum (17).
The novel and important findings are that: 1) ranolazine
00 to 1,000 mg twice daily had negligible effects on resting
R and SBP, unlike beta-blockers and HR-lowering
CBs, which fundamentally alter systemic hemodynamic
tatus; 2) at submaximal exercise (3 to 9 min), ranolazine
00 mg twice daily had negligible effects on RPP, whereas
,000 mg twice daily reduced RPP by 3.8% at 3 min and by
7
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anolazine 500 mg twice daily did not alter RPP, whereas
,000 mg twice daily reduced RPP by only 8%; 4) at
ubmaximal exercise (3 to 9 min), the reduction in ST-
egment depression from pre-exercise ranged from 15% to
0% with ranolazine 500 mg twice daily and from 30% to
5% with ranolazine 1,000 mg, whereas at peak exercise (12
in), the amount of ischemic ST-segment depression
ompared with placebo (and controlled for RPP) was
educed by 22% with ranolazine 500 mg twice daily and by
5% with 1,000 mg twice daily; and thus 5), compared with
lacebo, ranolazine produced a dose-dependent reduction in
T-segment depression that became more marked as
xercise-induced ischemia became more severe, indicating
hat the magnitude of ischemia reduction was out of proportion
o the minor reductions observed in HR or RPP.
What are the therapeutic implications of these findings
nd what does this tell us about mechanism of action of
anolazine? First, ranolazine seems to be unique therapeu-
ically in that the objective evidence of ischemia reduction
nd angina relief is not mediated by the traditional reduc-
ions in hemodynamic status and a decrease in myocardial
xygen demand. Second, anti-ischemic effects of ranolazine
ppeared only after a substantial amount of external cardiac
ork was achieved and ischemic ST-segment depressed had
ccurred (17). This suggests that the therapeutic benefits of
anolazine might be more regional (i.e., in ischemic myo-
ardial segments) rather than global (i.e., involving the entire
yocardium). Third, the clear improvements in angina and
yocardial ischemia observed in the present MARISA trial
nalysis are further reinforced by similar findings from both
he CARISA (Combination Assessment of Ranolazine in
table Angina) (18) and MERLIN (Metabolic Efficiency
ith Ranolazine for Less Ischemia in Non-ST Elevation
cute Coronary Syndromes) trials (19)—both of which
howed that exercise-induced ischemia and angina fre-
uency were reduced by ranolazine, whereas the MERLIN
rial showed further that the clinical end point of recurrent
schemia was reduced significantly by ranolazine. In partic-
lar, among the 55% of MERLIN trial patients who
xhibited a history of chronic angina before their qualifying
cute coronary syndrome event at the time of randomiza-
ion, ranolazine significantly reduced the composite trial
rimary end point of cardiac death, myocardial infarction,
nd recurrent ischemia (20).
Ischemia is associated with disruption in cellular sodium
nd calcium homeostasis. In ischemic cardiomyocytes, there
s an enhancement of late inward sodium current, which
eads to an excessive or pathologic leak of increased cytosolic
odium ion concentration, due to incomplete closure or
nactivation of the sodium channel (21–24). This, in turn, is
ollowed by an increase in intracellular calcium through the
odium–calcium exchanger, resulting in intracellular cal-
ium overload. Intracellular calcium overload causes ar-
hythmias and correlates well with increases in diastolic
ension. These regional lusitropic changes result in in- areased myocardial segmental stiffness—the earliest mani-
estations that precede regional ischemic contractile impair-
ent (21,22). This leads to increases in myocardial oxygen
onsumption of ischemic cells and further reductions in
egional myocardial blood flow to ischemic segments,
hereby exacerbating the imbalance between oxygen supply
nd demand. Thus, ischemia begets ischemia (Fig. 1 in
hryock and Belardinelli [25]).
Experimentally, ranolazine has been shown to selectively
nhibit late inward sodium current, which in turn disrupts
he vicious cycle of ischemia and consequently reduces the
yocardial oxygen supply-demand imbalance (26–28).
anolazine, by decreasing intracellular sodium-dependent
alcium overload, improves diastolic function, which has
een demonstrated clinically in patients with ischemic heart
ailure as well as in patients with ischemic heart disease who
ave shown improved LV regional diastolic function
29,30). The increase in regional peak filling rate after
anolazine administration might be attributed to the im-
rovement of regional relaxation in ischemic segments (31).
hus, an agent that reduces LV diastolic dysfunction would
ikely interrupt the earliest phase of the “ischemic cascade”
2,3); and ranolazine, as a positive lusitropic drug, would
ecrease myocardial oxygen consumption and improve an-
ina (29–31).
The authors hypothesize that the progressive magnitude
f ischemia reduction with ranolazine, which is out of
roportion to the minimal reductions in HR or RPP, “is
ikely due to an improvement (or preservation) in regional
oronary blood flow in areas of myocardial ischemia” (17).
lthough a recent scintigraphic imaging study does support
he observation that ranolazine might improve myocardial
erfusion in zones of myocardial ischemia during treadmill
xercise without alterations in HR or RPP at rest or during
eak exercise, these data were derived from an open-label,
onrandomized cohort of 27 patients and must be consid-
red hypothesis-generating (32). Additionally, Stone et al.
17) did not perform any direct measurements of myocardial
lood flow in the MARISA trial to support this potentially
mportant mechanism, and although plausible, this must
ontinue to be regarded as speculative.
In summary, ranolazine is an effective anti-anginal and
nti-ischemic agent that does not exert its therapeutic effects
hrough global hemodynamic alterations or significant re-
uctions in HR or RPP (17–19). As such, we might need to
dvance a different mechanistic paradigm (or revisit an old
ne) (1), that ranolazine acts as a positive lusitropic agent
hat improves regional LV diastolic dysfunction and seg-
ental ischemia through inhibition of exaggerated late
nward sodium current and a restoration of normal cellular
odium and calcium homeostasis (21,22,25,29–31). By
nterrupting the “ischemic cascade,” which begins with
egional diastolic dysfunction, ranolazine reduces myocar-
ial oxygen consumption of ischemic cells or segments and
hereby reduces exercise-induced ST-segment depression
nd angina. Future studies will be needed to further eluci-
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ine likewise favorably alters regional myocardial perfusion.
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